Page last updated: 2024-09-04

aclacinomycin and Anemia, Refractory, with Excess of Blasts

aclacinomycin has been researched along with Anemia, Refractory, with Excess of Blasts in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Hu, C; Jin, J; Lin, P; Lou, Y; Luo, Y; Ma, L; Mai, W; Mei, C; Meng, H; Qian, J; Qian, W; Ren, Y; Tong, H; Wei, J; Xie, L; Xu, G; Xu, W; Ye, L; Ye, X; Zhou, X	1

Other Studies

1 other study(ies) available for aclacinomycin and Anemia, Refractory, with Excess of Blasts

Article	Year
Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone. Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:5 Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies	2017

Article

Year

Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone.

Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:5

Topics: Aclarubicin; Adult; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabine; Decitabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Idarubicin; Karyotype; Male; Middle Aged; Mutation; Retrospective Studies

2017